I am a
Home I AM A Search Login

Papers of the Week


2022 Oct 18


Asian Pac J Allergy Immunol

Bosentan versus nifedipine in the treatment of vasculopathy in systemic sclerosis patients: A randomized control trial.

Authors

Phat T N, Luong V H, Minh V N, My L H, Phuong H T, Vinh N T H, Doanh L H
Asian Pac J Allergy Immunol. 2022 Oct 18.
PMID: 36278776.

Abstract

Bosentan is effective agent in scleroderma vasculopathy. However, there are no studies evaluating effectiveness of bosentan in Vietnamese patients, where nifedipine is still the common treatment.